BIOMAT Database Logo BIOMAT Database Logo

[Cases of eosinophilia in patients treated with Tocilizumab for rheumatoid arthritis]. 2022

Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Cabinet médical, Prilly centre, Route de Cossonay 28b, 1008 Prilly.

Hypereosinophilia is a haematological complication that can lead to severe organ damage. This article describes 2 patients who presented eosinophilia under treatment with tocilizumab for rheumatoid arthritis. We will describe the evolution of eosinophilia over time, with the monitoring of medication and discuss the potential link with the treatment as well as the importance of this manifestation in the context of the disease.

UI MeSH Term Description Entries
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
January 2016, RMD open,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Risk of infections in rheumatoid arthritis patients treated with tocilizumab.
May 2012, Rheumatology (Oxford, England),
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.
February 2012, Modern rheumatology,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Pulmonary Pasteurellosis in a Patient Treated With Tocilizumab for Rheumatoid Arthritis.
December 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
January 2017, Joint bone spine,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab.
June 2019, Journal of clinical laboratory analysis,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Tocilizumab for rheumatoid arthritis.
July 2010, The Cochrane database of systematic reviews,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Tocilizumab for rheumatoid arthritis.
January 2010, Drug and therapeutics bulletin,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases.
December 2011, Modern rheumatology,
Julie Vallat, and Amara Pieren-Salazar, and Christiane Zenklusen, and Laure Brulhart
Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?
February 2016, Rheumatology (Oxford, England),
Copied contents to your clipboard!